Synthetic Biology Group, Research Laboratory of Electronics, Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Curr Opin Microbiol. 2011 Oct;14(5):524-31. doi: 10.1016/j.mib.2011.07.028. Epub 2011 Aug 23.
Bacteriophage therapy for bacterial infections is a concept with an extensive but controversial history. There has been a recent resurgence of interest into bacteriophages owing to the increasing incidence of antibiotic resistance and virulent bacterial pathogens. Despite these efforts, bacteriophage therapy remains an underutilized option in Western medicine due to challenges such as regulation, limited host range, bacterial resistance to phages, manufacturing, side effects of bacterial lysis, and delivery. Recent advances in biotechnology, bacterial diagnostics, macromolecule delivery, and synthetic biology may help to overcome these technical hurdles. These research efforts must be coupled with practical and rigorous approaches at academic, commercial, and regulatory levels in order to successfully advance bacteriophage therapy into clinical settings.
噬菌体治疗细菌感染是一个具有广泛但有争议历史的概念。由于抗生素耐药性和毒力细菌病原体的发病率不断增加，最近人们对噬菌体重新产生了兴趣。尽管做出了这些努力，但由于监管、宿主范围有限、细菌对噬菌体的耐药性、制造、细菌裂解的副作用以及输送等挑战，噬菌体治疗在西方医学中仍然未得到充分利用。生物技术、细菌诊断、大分子输送和合成生物学的最新进展可能有助于克服这些技术障碍。这些研究工作必须与学术、商业和监管层面的实际和严格方法相结合，才能成功地将噬菌体治疗推进到临床环境中。
